[go: up one dir, main page]

AR085876A1 - Compuestos cristalinos de pirrolo[2,3-d]pirimidina - Google Patents

Compuestos cristalinos de pirrolo[2,3-d]pirimidina

Info

Publication number
AR085876A1
AR085876A1 ARP120101199A ARP120101199A AR085876A1 AR 085876 A1 AR085876 A1 AR 085876A1 AR P120101199 A ARP120101199 A AR P120101199A AR P120101199 A ARP120101199 A AR P120101199A AR 085876 A1 AR085876 A1 AR 085876A1
Authority
AR
Argentina
Prior art keywords
methyl
oxopropionitrile
pyrrolo
pyrimidin
piperidin
Prior art date
Application number
ARP120101199A
Other languages
English (en)
Inventor
Timothy D White
Brendan J Murphy
Christopher James Foti
Phillip J Johnson
Leonid A Margulis
Brian P Chekal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR085876A1 publication Critical patent/AR085876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que las contiene, sus preparaciones y sus usos para psoriasis.Reivindicación 1: Una forma cristalina de 3-((3R,4R)-4-metil-3-[metil-(7H-pirrolo[2,3-d]pirimidin-4-il)-amino]piperidin-1-il)-3-oxopropionitrilo caracterizada porque tiene un patrón de difracción de polvos por rayos X que comprende picos, en términos de 2q, a 6,4º, 14,3º y 17,0º 2q ± 0,2º 2q. Reivindicación 5: Una forma cristalina de 3-((3R,4R)-4-metil-3-[metil-(7H-pirrolo[2,3-d]pirimidin-4-il)-amino]piperidin-1-il)-3-oxopropionitrilo caracterizada porque tiene un patrón de difracción de polvos por rayos X que comprende picos, en términos de 2q, a 6,4º, 9,1º y 11,1º 2q ± 0,2º 2q. Reivindicación 9: Una forma cristalina de 3-((3R,4R)-4-metil-3[metil-(7H-pirrolo[2,3-d]pirimidin-4-il)-amino]piperidin-1-il)-3-oxopropionitrilo caracterizada porque tiene desplazamientos químicos de resonancia magnética nuclear 13C en estado sólido a 157,0, 151,0, 102,4, 44,8 y 32,7 ppm ± 0,2 ppm. Reivindicación 12: Una forma no cristalina de 3-((3R,4R)-4-metil-3[metil(7H-pirrolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il)-3-oxopropionitrilo caracterizada por un análisis físico o espectroscópico seleccionado del grupo que consiste en: a) un espectro de resonancia magnética nuclear 13C en estado sólido que comprende desplazamientos químicos a 161,9, 152,0, 103,3, 31,8, y 26,0 ppm ± 0,2 ppm; b) un grupo de bandas de Raman a 1311, 1506 y 2258 cm-1 ± 2 cm-1 y, c) un grupo de bandas infrarrojas a 1407, 1554 y 1647 cm-1 ± 2 cm-1.
ARP120101199A 2011-04-08 2012-04-09 Compuestos cristalinos de pirrolo[2,3-d]pirimidina AR085876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161473183P 2011-04-08 2011-04-08

Publications (1)

Publication Number Publication Date
AR085876A1 true AR085876A1 (es) 2013-10-30

Family

ID=45976456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101199A AR085876A1 (es) 2011-04-08 2012-04-09 Compuestos cristalinos de pirrolo[2,3-d]pirimidina

Country Status (16)

Country Link
US (1) US20120258976A1 (es)
EP (1) EP2694512A1 (es)
JP (1) JP2012219099A (es)
KR (1) KR101593768B1 (es)
CN (2) CN103459394B (es)
AR (1) AR085876A1 (es)
AU (1) AU2012241018B2 (es)
CA (1) CA2830463A1 (es)
HK (1) HK1208021A1 (es)
IL (1) IL228767A0 (es)
MX (1) MX2013009972A (es)
RU (1) RU2013144975A (es)
SG (1) SG193245A1 (es)
TW (1) TW201302758A (es)
WO (1) WO2012137111A1 (es)
ZA (1) ZA201306581B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
WO2014195978A2 (en) * 2013-06-05 2014-12-11 Msn Laboratories Limited PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
CN104678001A (zh) * 2013-12-03 2015-06-03 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定枸橼酸托法替尼及其光学异构体的方法
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
CN104926816A (zh) * 2014-03-19 2015-09-23 江苏先声药物研究有限公司 一种托法替布类似物及其制备方法与应用
CN106033064B (zh) * 2015-03-10 2019-05-07 上海上药信谊药厂有限公司 胆维丁测定方法
ES2882214T3 (es) * 2016-11-23 2021-12-01 Wuxi Fortune Pharmaceutical Co Ltd Forma cristalina y forma salina del compuesto 7h-pirrolo[2,3-d]pirimidina y procedimiento de preparación del mismo
KR102078805B1 (ko) * 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
CA3087124A1 (en) * 2018-01-09 2019-07-18 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN111670036B (zh) * 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
US12161748B2 (en) * 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
EP3787664B1 (en) 2018-05-03 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN108992454B (zh) * 2018-06-20 2020-06-02 合肥医工医药股份有限公司 一种治疗皮肤炎症性疾病的复方药物组合物
CN110286160A (zh) * 2018-06-22 2019-09-27 南京济群医药科技股份有限公司 一种枸橼酸托法替布残留溶剂的gc检测方法
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
KR102209701B1 (ko) * 2019-08-16 2021-01-29 유니셀랩 주식회사 토파시티닙의 신규한 결정형 형태 및 이의 제조방법
AU2020378151A1 (en) * 2019-11-08 2022-05-26 Cage Bio, Inc. Topical delivery of tofacitinib using ionic liquid
ES3038166T3 (en) * 2020-04-08 2025-10-09 Pfizer Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
MX2022013791A (es) * 2020-05-18 2023-02-15 Zim Laboratories Ltd Nueva composición de liberación prolongada de tofacitinib, sus derivados y sales.
WO2022013708A1 (en) * 2020-07-17 2022-01-20 Pfizer Inc. Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological conditions
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN113730335B (zh) * 2021-09-18 2023-07-28 中国药科大学 一种托法替布外用药物组合物及其应用
WO2023143345A1 (zh) * 2022-01-25 2023-08-03 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3536799A (en) * 1999-04-26 2000-11-10 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
ATE380031T1 (de) 1999-12-10 2007-12-15 Pfizer Prod Inc Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
AU2004224326B2 (en) * 2003-03-21 2010-04-22 Nexmed Holdings, Inc. Antifungal nail coat and method of use
US7052715B2 (en) * 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1913000B1 (en) 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders
EP2691395B1 (en) * 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts

Also Published As

Publication number Publication date
CN104610264A (zh) 2015-05-13
NZ616028A (en) 2015-11-27
AU2012241018A1 (en) 2013-10-10
CN103459394B (zh) 2016-04-27
US20120258976A1 (en) 2012-10-11
WO2012137111A1 (en) 2012-10-11
CA2830463A1 (en) 2012-10-11
EP2694512A1 (en) 2014-02-12
RU2013144975A (ru) 2015-05-20
KR101593768B1 (ko) 2016-02-12
CN103459394A (zh) 2013-12-18
ZA201306581B (en) 2014-11-26
IL228767A0 (en) 2013-12-31
MX2013009972A (es) 2013-09-26
AU2012241018B2 (en) 2015-11-12
HK1208021A1 (en) 2016-02-19
JP2012219099A (ja) 2012-11-12
TW201302758A (zh) 2013-01-16
KR20130132630A (ko) 2013-12-04
SG193245A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
AR085876A1 (es) Compuestos cristalinos de pirrolo[2,3-d]pirimidina
CL2012000795A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CL2014001529A1 (es) Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.
CL2007002607A1 (es) Compuestos derivados de aril-sulfonamida o piridin-sulfonamida; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o trastorno mediado por las interacciones de los linfocitos, tales como artritis reumatoide,
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
CL2014002301A1 (es) Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
SI3808749T1 (sl) Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni
EA201492125A1 (ru) НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2011001972A1 (es) Compuestos derivados de pirimidina fusionada, inhibidores akt; proceso de preparacion de dichos compuestos y compuestos intermediarios; compuestos intermediarios; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende y sus usos en el tratamiento de enfermedades hiperproliferativas.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
MX347765B (es) Inhibidores macrociclicos de la quinasa flt3.
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
ECSP099322A (es) Compuestos químicos
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
PH12014500758A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure